Cargando…
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer?
SIMPLE SUMMARY: Due to the lack of selectivity and the severe side-effects, cytostatics are the drugs of the present but not of the future and consequently new anticancer strategies must be developed. After binding to the neurokinin-1 receptor (NK-1R), NK-1R antagonists exert antitumor actions (anti...
Autores principales: | Muñoz, Miguel, Coveñas, Rafael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564414/ https://www.ncbi.nlm.nih.gov/pubmed/32962202 http://dx.doi.org/10.3390/cancers12092682 |
Ejemplares similares
-
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant
por: Coveñas, Rafael, et al.
Publicado: (2023) -
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia
por: Muñoz, Miguel, et al.
Publicado: (2020) -
Neurokinin-1 Receptor Antagonists against Hepatoblastoma
por: Muñoz, Miguel, et al.
Publicado: (2019) -
Neurokinin-1 Receptor Antagonists as Antitumor Drugs in Gastrointestinal Cancer: A New Approach
por: Muñoz, Miguel, et al.
Publicado: (2016) -
Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer
por: Coveñas, Rafael, et al.
Publicado: (2022)